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SUMMARY
Introduction. One of the most common neurological disorders is epilepsy, characterised by recurrent sponta-
neus seizures. Although not fully efficient in ca 30% of patients, pharmacologic treatment of epilepsy plays an 
important therapeutic approach not only against epilepsy.
Aim. To provide data on the mechanism of action, activity and neuroprotective efficacy in experimental con-
ditions, clinical efficacy against epilepsy and non-epileptic diseases of major, classical and newer antiepileptic 
drugs (AEDs – lamotrigine, topiramate, levetiracetam, valproate and carbamazepine).
Methods. A literature search for publications written in English, preferably published within a period of the last 
fifteen years, using the key words listed below.
Review. The majority of AEDs possess more than one mechanism of action. They exert their effect by acting 
on various receptors (different types of glutamatergic and mainly GABAA receptors), neurotransmitters (mainly 
glutamate or GABA) and voltage-gated ion channels (sodium or calcium ion channels). All reviewed AEDs pos-
sess neuroprotective activity, the weakest being carbamazepine. Apart from epilepsy, AEDs may be also used 
in the pharmacotherapy of migraine, neuropathic pain, spasticity, psychiatric disorders and Parkinsons’s or Alz-
heimer’s diseases.
Conclusions. As highlighted above, around 30% of epileptic patients do not substantially benefit from AEDs. It 
is possible that rational combinations of AEDs, based upon experimental studies, could improve this outcome. 
The neuroprotective effects of AEDs may point to their disease-modifying activity.
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INTRODUCTION
Epilepsy is a chronic and often progressive neurolog-
ical disorder characterised by recurrent spontaneous 
seizures, resulting from excessive, uncontrolled electri-
cal activity in the brain (Löscher and Potschka, 2002; 
Löscher, 2002; Murakami et al., 2007). It is generally 
defined by the occurrence of at least one unprovoked 
seizure (Fisher et al., 2005). Seizures can originate in 
one or more region of one or both hemispheres, or be-
gin simultaneously in both hemispheres (Löscher and 
Potschka, 2002). However, the most epileptogenic area 
of the brain is the medial temporal lobe (Löscher and 
Potschka, 2002; Cascino, 2008; Curia et al., 2008). Sub-
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sequently convulsions are generally classified into par-
tial (simple, complex and secondarily generalized), the 
most common, generalized (tonic, clonic, tonic-clon-
ic, absence, myoclonic and atonic) and unclassified 
seizures (Kwan and Brodie, 2000; Wojtal et al., 2006). 
Epilepsy not only affects brain physiology but it also 
influences human social, vocational and psychologi-
cal functioning (Dudra-Jastrzębska et al., 2007). The 
main goal in the treatment of epilepsy is to attain sei-
zure-freedom without producing antiepileptic drugs 
(AEDs) toxicity and without interfering with normal 
brain function (Małek et al., 2003; Cascino, 2008). The 
main two groups of AEDs are voltage-dependent sodi-
um or calcium channel blockers e.g.: carbamazepine 
(CBZ), gabapentin (GBP), lamotrigine (LTG), topira-
mate (TPM), valproate (VPA) which block sustained 
repetitive firing in individual neurons and drugs en-
hancing inhibitory events mediated by GABA: TPM 
and VPA. Nevertheless, most of AED possess more than 
one mechanism of action (Czapinski et al., 2005). The 
treatment of choice in epilepsy is based upon chronic 
administration of AEDs (Löscher and Potschka, 2002).
In about 30% of patients, this effect fails to be 
achieved because of pharmacoresistance (Kwan and 
Brodie, 2000; Sabers and Gram, 2000; Rigo et al., 2002). 
There are many possible causes of refractory epilepsy, 
the most important ones seem to be genetic, disease-
related and drug-related factors, which lead to insuf-
ficient seizure control (Löscher and Potschka, 2002). 
Mechanisms underlying the development of resistance 
are still elusive (Sabers and Gram, 2000; Rigo et al., 
2002). In this situation, polytherapy is attempted in or-
der to improve effectiveness. The polytherapy is based 
on combinations of AEDs with different mechanisms 
of action (Deckers et al., 2000; Małek et al., 2003). The 
most effective therapeutic scheme seems to be a com-
bination of a sodium channel blocker with a GABA-
ergic enhancer (Deckers et al., 2000). An additional 
way to deal with pharmacoresistance is by resective or 
disconnective surgery, which can provide substantial 
relief from seizures, functional improvement and in-
creased quality of patients’ lives. However, postopera-
tive complications may be associated with substantial 
rate of morbidity and even mortality, thus the risk/
benefit ratio should always be taken into consideration 
(Lee et al., 2008b). Vagus nerve stimulation on the oth-
er hand is a well-tolerated and effective therapeutic al-
ternative for epilepsy patients refractory to both med-
ical and surgical treatments, although its mechanisms 
of action are still not fully understood. Moreover, vagus 
nerve stimulation possesses cumulative efficacy with 
time (Lee et al., 2008c; Mapstone, 2008). Irrespective 
of the treatment followed, patients are considered free 
of seizures if they had not had seizures of any type for 
a minimum of one year while receiving the same dose 
of AEDs or while not taking any medication (Kwan 
and Brodie, 2000).
AIM
Our goal was to provide data from the relevant studies, 
preferably within the latest fifteen years, on AEDs: LTG, 
TPM, LEV, VPA and CBZ, in respect to their mecha-
nisms of action, human studies, activity profile in sei-
zure models and their possible neuroprotecive activity.
METHODS
 A literature search for publications written in English, 
preferably published within a period of the last fifteen 
years, using PubMed database and following key words: 
antiepileptic drugs, clinical efficacy, animal seizure 
models, neuroprotection, mechanisms of action, non-
epileptic conditions.
REVIEW
Mechanisms of action of AEDs
LTG [3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-tria-
zine] is a novel, second generation AED. It is assumed 
that LTG’s antiepileptic effect is mainly due to block-
ing the voltage sensitive sodium channels most effec-
tively in depolarized cells, resulting in the presynaptic 
inhibition of excessive release of excitatory amino ac-
ids, particularly glutamate and aspartate (Czapiński et 
al., 2005; Lasoń et al., 2011). LTG also affects GABA-
mediated synaptic transmission but there are conflict-
ing reports as to whether inhibitory transmission is en-
hanced or suppressed by LTG, and this drug has also 
been found to block glutamate AMPA receptors and 
reduce glutamate release in the rat dentate gyrus (Lee 
et al., 2008a).
TPM [2,3:4,5-bis-0-(1-methyl-ethylidene-)-B-D-
fruktopyranose sulfamate] is a newer AED, whose an-
ticonvulsant effect depends on diverse mechanisms: 
negative modulatory effect on AMPA subtype of glu-
tamate receptors (Schneiderman, 1998; Skradski and 
White, 2000; Świąder et al., 2005), attenuation of volt-
age – gated Na+ currents (Leach and Brodie, 1995), inhi-
bition of carbonic anhydrase (CA) isozymes, especially, 
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CA II and CA IV (Bialer et al., 2004), inhibition of as-
partate and glutamate release from the neuronal termi-
nals (White et al., 1997), enhancement of GABAA-me-
diated neurotransmission (Sabers and Gram, 2000; Li 
et al., 2002), inhibition of neuronal L-type high volt-
age-activated Ca2+ channels and modulatory effect on 
K+ channel currents (Zhang et al., 2000).
LEV [(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide] is 
a novel AED with a unique mechanism of action. Recent 
studies have demonstrated that the most relevant LEV 
mechanism of action is through binding to the synap-
tic vesicle protein SV2A (Lynch et al., 2004). However, 
it remains unknown how LEV modulates SV2A (Bialer 
et al., 2004). This drug has other mechanisms of action 
that likely play a smaller role: reversing the inhibition 
of neuronal GABA – and glycine-gated currents by the 
negative allosteric modulators zinc and beta-carbolines 
(Rigo et al., 2002), and partial depression of the type- 
N calcium current (Niespodziany et al., 2001; Lukya-
netz et al., 2002).
CBZ [5H-dibenzo[b,f]azepine-5-carboxamide] is 
a conventional, first generation AED, which is still 
widely used. The most important mechanism of ac-
tion is stabilization of the hyper-exited neuronal mem-
branes by blocking voltage sensitive Na+ channels (Tro-
jnar et al., 2002). This action inhibits both repetitive 
neuronal firing and the spread of discharges (Mac-
donald and Kelly, 1995). It also increases K+ conduc-
tance, modulates Ca2+ channel function (Czapiński et 
al., 2005; Stępień et al., 2005; Dudra-Jastrzębska et al., 
2007) and reduces glutamatergic transmission through 
NMDA-activated currents in cultured spinal cord neu-
rons (Łuszczki et al., 2005). The pharmacologically ac-
tive form of CBZ, oxidated by cytochrome P450 (Sar-
do and Ferraro, 2007) (by its isoforms CYP3A4 and 
CYP2C8), is carbamazepine-10,11-epoxide (CBZE). 
CBZE is catalysed by microsomal epoxide hydrolase to 
inactive trans-carbamazepine-10,11-diol (CBZD). CBZ 
and CBZD are urine flow dependant, about 1 mL/min 
and 8 mL/min respectively, but CBZD is relatively in-
dependent of urine flow (Stępień et al., 2005; Perucca, 
2006; Zaremba et al., 2006; Tutor-Crespo et al., 2008).
VPA (2-propylpentanoic acid) is one of the most 
commonly used older AEDs (Xia et al., 2006). As for the 
molecular mechanisms of action of VPA, the drug locks 
the voltage-dependent Na+ and Ca2+ channels and ac-
tivates K+ conductance in neurons (Dudra-Jastrzębska 
et al., 2007), potentiates GABA-ergic transmission in 
speciﬁc brain regions, increases synthesis of GABA by 
activating the GABA-synthesizing enzyme glutam-
ic acid decarboxylase and increases the potassium-in-
duced release of GABA in cortical neurons (Wilby et 
al., 2005; Łuszczki et al., 2009), inhibits enzymes in-
volved in GABA degradation including GABA-trans-
aminase and succinic semialdehyde dehydrogenase 
(Owens and Nemeroff, 2003; Łuszczki et al., 2009). In 
addition, VPA reduces the level and release of the ex-
citatory amino acid aspartate in the brain and attenu-
ates neuronal excitation by the reduction of activation 
of NMDA receptors (Czapiński et al., 2005; Łuszczki et 
al., 2009). There is also a theory that VPA is connect-
ed with protein kinase C (PKC), mainly as its inhibi-
tor (Löscher, 2002; Toth, 2005).
Human studies
LTG is widely used for seizure control in epilepsy, es-
pecially in patients with generalized tonic-clonic sei-
zures and partial convulsions with or without second-
ary generalization, and in other neurologic and psychi-
atric disorders (Zakrzewska et al., 1997). This AED is 
used as add-on treatment for patients with refractory 
epilepsy and as monotherapy in newly diagnosed epi-
Table 1. Mechanisms of action of antiepileptic drugs
Lamotrigine Topiramate Levetiracetam Carbamazepine Valproate
Na+ channels – – – –
GABA receptors +/– + +
– (only increase in 
GABA level) 
Ca2+ channels – N, P/Q, R, T-types – (L-type) – (N-type, partial) – – (T-type)
K+ channels + + +
Glutamate receptors – (AMPA) – (AMPA) – (NMDA)
Other – CA II and CA IV
Modulates SV2A 
binding site 
– protein kinase C
(+) activator; (–) inhibitor; () no effect, CA – carbonic anhydrase. Data presented in Table 1 was based on Czapiński et al., (2005) and Lasoń 
et al. (2011)
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lepsy (Brodie and Schachter, 2001). It has been found to 
have similar effectiveness to valproic acid. Dinnerstein 
et al. (2007) described a case of LTG intoxication pro-
voking status epilepticus in an adult with localization 
– related epilepsy. Their article demonstrated the pro-
convulsant effects of LTG therapy, mostly in childhood 
conditions such as benign focal epilepsy of childhood 
with centrotemporal spikes, severe myoclonic epilep-
sy of infancy, Lennox-Gastaut syndrome and juvenile 
myoclonic epilepsy. Moreover, nonconvulsive status 
epilepticus has been associated in 3 patients with idio-
pathic generalized epilepsy. The data also indicate that 
LTG can be effective in neuropathies. It was significant-
ly better than placebo in the management of trigeminal 
neuralgia (Zaremba et al., 2006). In two other studies, 
significant reduction of pain has been also shown in 
patients with HIV-associated neuropathy (Sindrup and 
Jensen, 2002) and poststroke pain (Vitezic et al., 2008). 
The dose of LTG was usually 50 mg/day and increased 
by 50 mg weekly up to 300–400 mg. Calabrese et al. 
(1999) provided data from 199 patients that LTG was 
an effective treatment for bipolar depression and safe, 
because it did not increase the risk of inducing mania. 
Morover, data suggest that combined treatment of LTG 
and lithium can be beneficial for patients with bipolar 
disorder (Bialer et al., 2004). In patients with Alzhei-
mer’s disease, cocaine addiction and mood disorders, 
LTG was associated with promising outcomes (Mar-
golin et al., 1998; Frye et al., 2000). Lampl et al. (2005) 
have indicated that LTG is highly effective in reducing 
migraine aura and migraine attacks.
TPM is efficacious in patiens with various types of 
epileptic attacks, especially in patients with refracto-
ry chronic partial epilepsies in short-term controlled 
clinical trials (Kelly et al., 2002; French et al., 2004; 
Majkowski, 2004a; Stępień et al., 2005). Bootsma et al. 
(2004) have reported that long-term retention, effica-
cy and side effect profiles for TPM have not been suf-
ficiently investigated. They concluded that TPM was 
associated with a high incidence of side effects in clin-
ical practice. The data have provided evidence, that 
TPM is effectively used as monotherapy in newly di-
agnosed adolescents and adults with partial or mixed 
seizures (Stępień et al., 2005). French et al. (2004) stat-
ed that TPM was appropriate for adjunctive treatment 
of refractory partial seizures in adults and effective 
for the treatment of refractory partial seizures in chil-
dren. Another study evaluated the effectivevenss of 
TPM (200 mg/day) added to CBZ (without or with an 
additional AED) in 264 patients with localization-re-
lated epilepsy in a multicenter, double-blind, and place-
bo-controlled trial (Majkowski et al., 2005). The main 
finding of this study has revealed that most of the ad-
verse effects ascribed to TPM have a tendency to dis-
appear over time. TPM is also an effective option for 
patients with juvenile myoclonic epilepsy (Biton and 
Bourgeois, 2005; Sousa Pda et al., 2005). Noteworthy, 
TPM is effective practically against all types of epilep-
tic seizures (Czapiński et al., 2005). In other interest-
ing studies, TPM was administered to eight patients 
with trigeminal neuralgia – the doses ranged from 50 
to 100 mg a day. The authors suggest that TPM can be 
considered an alternative treatment for patients with 
trigeminal neuralgia (Domingues et al., 2007). Howev-
er, there were no beneficial effects of TPM in patients 
with trigeminal neuralgia in the multicenter, double-
blind study (Gilron et al., 2001; Zaremba et al., 2006). 
TPM proved to be effective in the treatment of chron-
ic daily headache (CDH) due to probable chronic mi-
graine and with probable medication abuse in de novo 
migraine patients (Gracia-Naya et al., 2007). Similarly, 
the Dahlof et al. (2007) study has shown that TPM at 
a daily dose of 100 mg significantly improved daily ac-
tivities in patients with migraine. Daily function and 
health status significantly improved for those achiev-
ing a > or = 50% migraine frequency reduction. Ferra-
ro and Di Trapani (2008) have reported, that TPM is 
effective in the preventive treatment of pediatric mi-
graine. TPM dosages (2–3 mg/kg/day) are much lower 
than the doses recommended for the adjunctive treat-
ment of epilepsy (5–9 mg/kg/day).
LEV is recommended as an add-on therapy in refrac-
tory partial epilepsy (Otoul et al., 2005). It has been al-
so demonstrated effective as adjunctive therapy for pri-
mary generalized tonic-clonic seizures and myoclonic 
seizures of juvenile myoclonic epilepsy. Other studies 
have indicated that intravenous LEV (at a dose of 1000–
1500 mg administered over 5 minutes) may be consid-
ered in the treatment of nonconvulsive or focal status 
epilepticus refractory to initial therapy (Marson et al., 
2001; Zaccara et al., 2006). Hawker et al. (2003) have 
demonstrated that LEV is effective in reducing pha-
sic spasticity but not tonic spasticity in patients with 
multiple sclerosis.
CBZ is effective in the treatment of simple or com-
plex partial seizures (Marson et al., 2007; Wheless et al., 
2007) and secondarily generalized tonic-clonic seizures 
in adults and children (Sobaniec et al., 2005; Tutor-Cre-
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spo et al., 2008). In the survey performed by Wheless et 
al. (2007), the experts choose CBZ as the drug of choice 
for initial monotherapy in partial seizures. Pain relief 
or a reduced pain ratio occurs at a CBZ dose of 100–
2400 mg in 70% of patients, in contrast to those re-
ceiving placebo. Moreover, the doses between 100 and 
400 mg per day showed effectiveness in relieving par-
esthesia (Restless legs syndrome – RLS) (Zaremba et al., 
2006). In addition, CBZ can also be used in various dis-
orders like acute mania, trigeminal neuralgia, noctur-
nal enuresis or prophylaxis of manic-depressive dis-
orders unresponsive to lithium (Sobaniec et al., 2005). 
CBZ proved to be effective in bipolar disorder; a sur-
vey of 400 patients showed that approximately 70% re-
sponded positively (Zaremba et al., 2006). However, in 
patients with schizophrenia CBZ showed a decrease in 
aggressive behaviour, anxiety and depression, but did 
not affect the main symptoms (hallucinations and de-
lusions) (Zaremba et al., 2006). There were many stud-
ies to determine other therapeutical effects of CBZ but 
they showed lack of effectiveness in Binge eating dis-
order (BED), post-herpetic neuralgia and only margin-
al analgesic effect in painful diabetic neuropathy (Za-
remba et al., 2006). CBZ was the first AED used in bi-
polar disorder. There were many double-blind studies 
confirming the efficacy of CBZ and its derivate-oxcar-
bazepine. Moreover, a significant positive response was 
achieved in 70% of over 400 patients with mania. CBZ 
also showed similar therapeutic effects as lithium and 
chlorpromazine (Zaremba et al., 2006). The studies con-
ducted in schizophrenic patients showed that admin-
istration of CBZ could reduce anxiety, aggressive be-
havior and depression. Again, there is no effect of this 
AED against other psychotic symptoms like hallucina-
tions and delusions. Consequently, CBZ should be rec-
ommended in the form of combined therapy with neu-
roleptics, only in patients demonstrating hyperactivi-
ty, violent outbursts and affective symptoms (Zarem-
ba et al., 2006).
VPA is recommended as the treatment of choice for 
generalized tonic-clonic seizures, absence seizures, and 
myoclonic seizures (Vazquez, 2004; Blaheta et al., 2005). 
The data show that VPA is effective and is associated 
with acceptable tolerability as first-line monotherapy 
in focal onset epilepsy, also (Jędrzejczak et al., 2008).
With regards to migraine prophylaxis, VPA has 
shown its effectiveness in two double-blind, placebo-
controlled studies. The significant reduction of days 
with migraine headaches and good toleration were re-
ported in both studies (Zaremba et al., 2006). As for bi-
polar disease, VPA is approved for the treatment of its 
manic phase (Lin et al., 2006). Two randomized, multi-
center, double-blind clinical trials confirmed that over-
all outcomes were significantly better than in the pla-
cebo group (Bowden et al., 2000; Zaremba et al., 2006). 
There are some case reports showing effectiveness of 
VPA in the treatment of trigeminal neuralgia, post-her-
petic neuropathy and other neuropathies. In some pa-
tients, VPA relieved pain, although other studies show 
that there is no significant effect in placebo-controlled 
trial (Zaremba et al., 2006). VPA is commonly admin-
istered as combination therapy for the treatment of 
schizophrenia, especially in aggressive patients. How-
ever, there is no significant evidence that VPA is effica-
cious based on large placebo-controlled trials (Zaremba 
et al., 2006). Slow-release VPA signifcantly decreased 
the subjectively rated intensity of RLS complaints and 
duration of symptoms compared to placebo (Eisensehr 
et al., 2004; Conti et al., 2008). The combination of VPA 
and amiloride compared to VPA alone, is associated 
with an increase in protective action against MES-in-
duced seizures (Macdonald and Kelly, 1995).Addition-
al data show that VPA inhibits the proliferation of cul-
tured human neuroblastoma cells in vitro and in vivo 
(Cinatl et al., 2002; Eyal et al., 2006). Eyal et al. (2006) 
have reported that VPA increased P-glycoprotein ex-
pression and function in human tumour cell lines and 
in rat liver.
Activity profile of AEDs in seizures models
LTG is effective against maximal electroshock (MES)-
induced seizures, which may be regarded as an exper-
imental model of generalized tonic-clonic seizures and, 
to a certain degree, of partial seizures with or without 
secondary generalization (Löscher et al., 1991). It has 
been shown, in animal models, that LTG is less effective 
against generalized tonic clonic seizures when NMDA-
mediated neurotransmission is augmented (Tomczyk 
et al., 2007). In the MES test, Borowicz et al. (2002b) 
evaluated the influence of aminophylline on the pro-
tective activity of LTG. The data indicate that amino-
phylline reduced the anticonvulsive effect of this drug 
in the MES test in mice. However, in contrast to ami-
nophylline, another methylxanthine derivative, caf-
feine (1,3,7-trimethylxantine) did not affect the pro-
tective action of LTG against MES in mice (Jankiewicz 
et al., 2007). Sardo and Ferraro (2007) suggested a re-
lationship between the nitric oxide (NO) system and 
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the anticonvulsant effect of LTG which could be en-
hanced by reducing NO levels and, conversely, damp-
ened by an increased nitrergic activity. They used an 
experimental model of partial complex epilepsy: the 
maximal dentate gyrus activation (MDA). Łuszczki et 
al. (2008) evaluated interactions of the NMDA receptor 
antagonist MRZ 2/576 (8-chloro-4-hydroxy-1-oxo-1,2-
dihydropyridazinol (4,5 – b) quinoline-5-oxide choline 
salt) and LTG in the MES model. In this test, MRZ did 
not significantly affect the antiseizure effects of LTG. 
Among three calcium channel inhibitors studied, only 
amlodipine in subthreshold doses was able to potenti-
ate the anticonvulsant activity of LTG in mice against 
MES, whilst diltiazem and amlodipine were ineffec-
tive (Łuszczki et al., 2007b). The aim of the Vitezic et 
al. (2008) study was to investigate the Na+-K+-ATPase 
activity in the hippocampus and cortex of rats follow-
ing kainic acid (KA)-induced convulsions. Further, this 
study was also designed to investigate the influence of 
LTG pre-treatment on the mentioned hippocampal and 
cortex changes. KA systemic application resulted in Na+, 
K+-ATPase activity inhibition in the rat hippocampus 
and cortex and LTG pre-treatment was associated with 
a partially protective effect on enzyme activity.
In animal models of epilepsy, TPM is effective against 
major experimental convulsive procedures: MES-in-
duced seizure, audiogenic seizures in DBA/2 mice, 
amygdala – kindled rats and pentylenetetrazole (PTZ) 
– induced convulsions (Nakamura et al., 1994; De Sarro 
et al., 2000). Experimental data have shown that TPM 
enhances the protective potential of conventional AE-
Ds in animal models of epilepsy. Łuszczki et al.(2009) 
have demonstrated synergistic cooperation of TPM and 
gabapentin (GBP) in MES – induced seizures in mice. 
However, it is inactive or weakly active in seizures in-
duced by picrotoxin (PTX), pentetrazole (PTZ), bicu-
culline (BIC) and strychnine (Sills et al., 2004; Stępień 
et al., 2005). No pharmacokinetic interactions among 
these AEDs and lack of acute adverse effects, make the 
combination of TPM and GBP very important for pa-
tients with refractory epilepsy (Sills et al., 2004).
Świąder et al. (2005) in their study have indicated 
that N-methyl-D-aspartate (NMDA) and KA, which 
are glutamate receptor agonists, and the GABAA recep-
tor antagonist – bicuculline (BIC), reduced the antisei-
zure potency of TPM against MES in mice. Recent ex-
perimental data have shown that caffeine, a methylx-
anthine derivative, decreased the protective potential 
of TPM against MES in mice (Chrościńska et al., 2007; 
Jankiewicz et al., 2007).
Czapiński et al. (2005) have reported that LEV is ef-
fective against amygdala-kindling in rats and in genet-
ic models of epilepsy. However, this AED is ineffective 
against MES- induced seizure or the clonic phase of sei-
zures provoked by picrotoxin (PTX) or by other chem-
ical convulsants. Other interesting studies have indi-
cated that the anticonvulsant efficacy of LEV is syner-
gistically and substantially enhanced by GABA-ergic 
drugs in amygdala-kindled rats and audiogenic seizures 
in mice. In a rat model of experimental status epilep-
ticus, the combination of LEV and diazepam (DZP) is 
associated with anticonvulsant synergy (Patsalos, 2004). 
Doheny et al. (2002) have shown, that LEV adminis-
tration was associated with a dose-dependent reduc-
tion in the frequency of generalized and non-general-
ized seizures in the tetanus toxin seizure model, which 
is considered to reflect human complex partial epilep-
sy. Other data have indicated that LEV did not impair 
cognitive functions in experimental animals or epilep-
tic patients (Czapiński et al., 2005).
The duration of EMG (electromyographic activi-
ty) induced by MES was shortened by CBZ at a dose 
of 20 mg/kg. Similar effects were observed in the du-
ration of tonic extension seizures. Strange as it may 
seem but almost the same effects were observed by 
administrating CBZ orally (Murakami et al., 2007). 
In the MES test in mice D-(–)-3-(2-carboxypiperazin-
4-yl)propyl-1-phosphonate (D-(–)CPP) and D,L-3-(±)-
(2-carboxypiperazin-4-yl)propyl-1-phosphonate ((±)-
CPP), both competitive NMDA receptor antagonists, 
at a dose of 0.625 mg/kg potentiated the anticonvul-
sive action of CBZ, without influencing its plasma lev-
els and producing significant adverse effects. Moreover, 
D-CPP even at the dose of 1 mg/kg was free of adverse 
effects but still enhanced the anticonvulsive actions 
of CBZ (Wojtal et al., 2006). Borowicz et al. (2007b) 
have demonstrated that both acute and chronic fluox-
etine, a serotonin uptake inhibitor, enhances the anti-
convulsive action of many AEDs, including CBZ. In 
an acute and chronic experimental protocol, f luox-
etine (at 15 mg/kg) reduced the ED50 value of CBZ by 
76,5% and 22.5% respectively. However fluoxetine in-
creased the brain concentration of CBZ, pointing to 
a pharmacokinetic mechanism of this interaction. In 
another study, Borowicz et al. (2007a) showed that mi-
anserin at 30 and 40 mg/kg elevated the electroconvul-
sive threshold; however, when administered at its sub-
effective dose of 20 mg/kg, the anticonvulsant action 
of CBZ was enhanced and a lowering of its ED50 value 
by 53% ocurred. In contrast, chronic administration 
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of mianserin (30 mg/kg) did not lower the electrocon-
vulsive threshold. After acute administration, the an-
tidepressant at subeffective doses diminished the an-
ticonvulsant activity of CBZ (Borowicz et al., 2007a). 
2-Chloro-N6-cyclopentyladenosine (CCPA, a selective 
adenosine A1 receptor agonist) administered at a sub-
threshold dose of 0.125 mg/kg potentiated the anticon-
vulsant activity of CBZ against MES. Systemic admin-
istration of DPCPX (a selective A1 receptor antagonist) 
reversed the action of CCPA. CBZ in combination with 
CCPA did not interfere with the normal behavior of 
animals, since neither motor coordination nor long-
term memory were altered (Łuszczki et al., 2005). The 
protective activity of CBZ against MES in mice is also 
significantly increased by 2-chloroadenosine (a non-
selective adenosine A1/A2 receptor agonist) at a dose 
of 0.125 mg/kg. At the higher dose (1 mg/kg), 2-chlo-
roadenosine is able to augment the anticonvulsant ef-
fect of CBZ against pentylenetetrazol-evoked seizures. 
The potentiated protective action of CBZ is reversed 
by aminophylline, a non-selective adenosine recep-
tor antagonist (at 5 mg/kg), and 8-cyclopentyl-1,3-di-
methylxanthine (8-CPX), a selective A1 adenosine re-
ceptor antagonist (at 5 mg/kg). 2-Chloroadenosine ad-
ministered with or without AEDs did not cause either 
motor or long-term memory impairment (Borowicz 
et al., 2002a). Chronic amiloride, at the dose of 75 and 
100 mg/kg, significantly enhanced the protective ac-
tion of CBZ against MES-induced seizures, which was 
however accompanied by an increase in total CBZ brain 
concentration (Łuszczki et al., 2009). In the study per-
formed by Łuszczki et al. (2008) agmatine showed no 
effect on the anticonvulsant action of CBZ in MES test 
in mice. On the other hand, some competitive NMDA 
receptor antagonists (such as LY235959, LY233053, D-
CPP-ene, and procyclidine) enhanced the anticonvul-
sant action of CBZ in the MES test in mice.
VPA exerts anticonvulsant effects in almost all an-
imal models of seizures such as MES, PTZ and amyg-
dala-kindling (French et al., 2004).
Łuszczki et al. (2008) evaluated interactions of ag-
matine and VPA in the MES seizure model. In this ex-
periment, agmatine enhanced the antiseizure activity 
of VPA. Moreover, some competitive NMDA receptor 
antagonists (such as LY235959, LY233053, D-CPP-ene 
and procyclidine) also augmented the anticonvulsant 
activity of VPA. The anticonvulsant effect of VPA is sig-
nificantly increased by dizocilpine (MK-801), an open 
NMDA receptor channel blocker, in doses of 0.0125 
and 0.05 mg/kg. Łuszczki et al. (2007b) have reported 
that furosemide, administered at a dose of 100 mg/kg 
markedly potentiated the anticonvulsant effects of 
VPA, however, other AEDs were unaffected. Notewor-
thy, furosemide did not affect the free plasma and to-
tal brain VPA concentrations (Łuszczki et al., 2007a). 
The combination of VPA and amiloride, as opposed 
to VPA alone, has shown an increase in its protective 
action against MES-induced seizures (Łuszczki et al., 
2009). The anticonvulsant action of VPA is similar to 
that of CBZ in that it was potentiated by D-CPP and 
CPP (two uncompetitive NMDA receptor antagonists 
at 0.625 mg/kg) in the MES test in mice, without any 
pharmacokinetic mechanisms involved. Moreover, D-
CPP, even at the dose of 1 mg/kg, was free of adverse 
effects but still enhanced the anticonvulsant activity 
of VPA. However, in contrast to CBZ, VPA, in combi-
nation with CPP or D-CPP caused a moderate motor 
impairment (with CPP) and a significant impairment 
of long-term memory and motor coordination (with 
D-CPP) (Cinatl et al., 2002). Administration of fluox-
etine, both acutely and chronically, enhances the anti-
convulsive action of VPA. In the acute and chronic ex-
perimental protocol, fluoxetine, both at 15 mg/kg, re-
duced the ED50 value of VPA by 28.1% and 20%, respec-
tively (Borowicz et al., 2007b). Borowicz et al. (2007a) 
showed that mianserin, at 30 and 40 mg/kg, elevated 
the electroconvulsive threshold, however, when ad-
ministered at its subeffective dose of 20 mg/kg, it en-
hanced the anticonvulsant action of VPA and lowered 
its ED50 value by 24% against MES. In contrast, chronic 
application of mianserin at 30 mg/kg, resulted in a re-
duction of the anticonvulsant action of VPA by 33% 
(against MES in mice). Tricyclic antidepressants, giv-
en acutely, imipramine and amitriptyline but not de-
sipramine, potentiated the protective efficacy of VPA 
against MES-induced seizures.There are data showing 
negative influence of VPA on total distance moved by 
mice and the velocity, even after drug withdrawal. The 
significant TH immunoreactive cell loss in the substan-
tia nigra suggests cell death in the motor system is oc-
curring (Eyal et al., 2006).
Mechanisms of action of AEDs on neuroprotection
In the Papazisis et al. (2008) study a well-established 
model of perinatal asphyxia in 7-day-old rats was used 
to investigate the effect of LTG on hypoxic-ischemic 
(HI)-induced damage to different hippocampal brain 
structures. Their results suggest a neuroprotective ef-
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fect of LTG in this particular animal model of neona-
tal HI encephalopathy. Another interesting study has 
demonstrated that sipatrigine (BW619C89), a deriva-
tive of LTG, has potent neuroprotective properties in 
animal models of cerebral ischemia and head injury 
(Calabresi et al., 2000). Lee et al. (2000) have indicat-
ed that LTG and MK-801 (dizocilpine) are effective in 
attenuation of brain lesions induced by 3-nitropropi-
onic acid. A higher dose of LTG (20 mg/kg) is associ-
ated with a better neuroprotective effect than MK-801 
(2 mg/kg per day). Other data reveal that LTG reduc-
es hippocampal neuronal damage in animal models of 
cardiac arrest-induced global cerebral ischemia (Shuaib 
et al., 1995; Wiard et al., 1995; Crumrine et al., 1997; 
Trojnar et al., 2002). In a KA-induced model of status 
epilepticus in rats, LTG has reduced hippocampal neu-
ronal loss even at doses not protecting from seizures. 
The authors suggest that seizure prevention and neu-
roprotection might not be tightly coupled (Maj et al., 
1998). Another study has demonstrated that mild hy-
pothermia associated with LTG treatment is more ef-
fective in neuroprotection than hypothermia or LTG 
alone. The authors conclude that the combination of 
LTG with mild hypothermia could increase its neuro-
protective properties (Koinig et al., 2001).
Hanaya et al. (1998) have demonstrated that TPM 
dose-dependently reduces the severity of kindled sei-
zures. The administration of TPM after experimental 
status epilepticus in adult male Wistar rats attenuates 
seizure-induced hippocampal neuronal injury (CA1 
and CA3 area). Other studies have demonstrated that 
TPM, when administered post-insult in vivo, is protec-
tive against selective hypoxic-ischemic white matter in-
jury (Follet et al., 2004; Stępień et al., 2005). Also, Le-
ker et al. (2003) have underlined that TPM is effective 
in global and focal ischemia. Another interesting study 
has demonstrated that early administration of a neuro-
protective agent in combination with later-onset cool-
ing could represent an effective therapeutic interven-
tion after neonatal hypoxia-ischemia (Liu et al., 2004). 
In a rat model of focal cerebral ischemia, TPM has al-
so proved to be neuroprotective. Treatment with this 
drug, 2 hours after the right middle cerebral artery em-
bolization, resulted in a dose and use-dependent pro-
tection of neurons (Yang et al., 1998).
Animal studies have shown that LEV is an effective 
neuroprotectant in focal ischemia (Leker and Neufeld, 
2003). Other studies have shown that LEV exhibits neu-
roprotection in a rat model of focal cerebral ischemia 
(Hanon and Klitgaard, 2001). Mazarati et al. (2004) 
have demonstrated that LEV possesses neuroprotec-
tive activity in experimental status epilepticus. How-
ever, Pitkanen (2002) has indicated that LEV did not 
reduce hippocampal damage after pilocarpine – in-
duced status epilepticus when assesssed 3 weeks later.
CBZ protects only partially against pyramidal cell 
damage and seems to be less efficacious in terms of neu-
roprotection than the novel AED in experimentally-in-
duced status epilepticus. Moreover, the drug protect-
ed neither against the hilar somatostatin-immunore-
active neuron loss nor the spatial learning deficit (Mu-
rakami et al., 2007). It has been documented that CBZ 
has neuroprotective properties in a model of ischemic 
stroke. Moreover, CBZ reduces cerebral perfusion and 
is a CNS depressant (Zaremba et al., 2006).
VPA, when given chronically, was shown to distinct-
ly protect hippocampal neurons in rats subjected to 
self-sustaining status epilepticus, evoked by prolonged 
electrical stimulation of the basal amygdala (Morland 
et al., 2004). Interestingly, this clear-cut neuroprotec-
tion was associated with much better behavioral out-
come (less hyperexcitability or locomotor hyperactiv-
ity) when compared to non-treated controls. Notewor-
thy, VPA did not suppress the following spontaneous 
seizure activity (Brandt et al., 2006). According to Bo-
lanos et al. (1998), chronic administration of VPA did, 
however, inhibit the development of spontaneous con-
vulsions in rats exposed to kainic acid-induced status 
epilepticus. Moreover, VPA decreased damage follow-
ing transient focal cerebral ischemia or ischemia-re-
perfusion injury in the rat brain (Ren et al., 2004; Su-
da et al., 2013).
CONCLUSIONS
Epilepsy is one of the most common neurological disor-
ders – it affects about 1% of the worldwide population, 
which is about 50 million people. Each year 20 to 70 
per 100 000 incidents of the disease are registered. The 
therapy leading to long-standing remissions is achieved 
only in 70–80% of cases. The difficulties in the therapy 
of epilepsy arise from its yet mostly unknown etiology. 
Epilepsy is comprised of periodic disturbance in neu-
ronal activity, which results from excessive discharges 
of brain cortex, limbic system or brain trunk neurons. 
For both first and second line treatment, convention-
al AEDs are used in generalized tonic-clonic seizures, 
simple partial complex partial seizures and myoclonic 
epileptic attacks (Kelly et al., 2002). Among these ther-
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apeutic agents CBZ and VPA are prominent (Kelly et 
al., 2002). These AEDs act via diverse mechanisms of 
action, although the majority block voltage-dependent 
sodium channels and enhances GABA-ergic inhibito-
ry neurotransmission. LTG, TPM and LEV are newer 
AEDs, whose anticonvulsant effect depends on a vari-
ety of mechanisms. Although a substantial amount of 
experimental data on the effective synergistic combi-
nations of AEDs is available (Czuczwar et al., 2009a,b), 
there is an urgent need for multicenter studies and de-
velopment of standards on this issue in drug-resistant 
epileptic patients (Majkowski, 2006). Drug resistance in 
epilepsy, although not entirely understood, seems to re-
sult from disturbed pharmacological targets (i.e. GABA 
receptors) or an overexpression of protein AED trans-
porters (Majkowski, 2004b). Probably, synergistic AED 
combinations, derived from preclinical studies, could 
be of value to drug resistant epileptic patients, but this 
needs, as mentioned above, careful clinical verification.
 An increasing role of AEDs in the treatment of oth-
er (besides epilepsy) conditions is emerging. Especial-
ly neurological and psychiatric disorders can benefit 
from these drugs. In neuropathies, VPA and LTG can 
be effective; these AEDs were also effective in the treat-
ment of bipolar depression. The other AED – TPM has 
been used in patients with trigeminal neuralgia. In pa-
tients with Alzheimer’s disease, cocaine addiction and 
mood disorders, LTG was associated with promising 
outcomes. Some AEDs are effective in reducing mi-
graine attacks. These include: LTG, TPM and VPA. One 
of the second generation AEDs: LEV is effective for re-
ducing phasic spasticity in patients with multiple scle-
rosis. CBZ is effective in acute mania, trigeminal neu-
ralgia, nocturnal eneuresis and bipolar disorders. Per-
spectives for the use of novel AEDs in conditions oth-
er than epilepsy look promising. These drugs are rec-
ommended especially in disorders where the available 
treatment has proved to be ineffective.
One of the above presented AEDs, LTG, has a dis-
tinct neuroprotective profile in animal models of ce-
rebral ischemia. This drug was also associated with 
neuroprotective effects in a KA-induced model of sta-
tus epilepticus. Another AED, TPM, very potently pre-
vented neuronal loss in hippocampus exposed to pro-
longed seizure activity (Remy and Beck, 2006). Addi-
tional data have demonstrated that TPM is protective 
against selective hypoxic – ischemic white matter in-
jury (Domingues et al., 2007) and ischemia. Another 
new AED, LEV, is effective in focal cerebral ischemia. 
Last, but not least, VPA displayed potent neuroprotec-
tive activity in models of status epilepticus and isch-
emia, also significantly affecting post-status epilepti-
cus behavior. Neuroprotective effects of AEDs in sei-
zure models, and especially that of VPA, may point to 
the epilepsy-modifying activity. However, the problem 
with neuroprotection by AEDs may be that a full ex-
trapolation from animal studies to human conditions 
is not fully possible.
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